Events

This is a promotional website intended for healthcare professionals in the UK and Ireland only.
Back to Events

30th November 2022 6:30PM GMT - Virtual

The changing landscape of Waldenström’s Macroglobulinemia (WM) in Scotland

‘The changing landscape of Waldenström’s Macroglobulinemia (WM) in Scotland’ was a live virtual meeting.

agenda

Discussion topicDiscussion Lead
WelcomeDr Pam McKay
The history and background of WM in ScotlandDr Pam McKay
Current treatments: BSH guidelinesDr Dima El-Sharkawi
An in-depth look at the ASPEN studyDr Shirley D’Sa and Dr Roger OwenDr Jaimal Kothari
Practical considerations of BRUKINSA®Dr Jaimal Kothari
Panel discussionDr McKay, Dr El-Sharkawi ad Dr D’Sa
CloseDr Pam McKay

Recording

The Changing Landscape of WM in Scotland with Dr Pam McKay

Date of preparation: November 2022. 1122-BRU-PRC-067

Current Treatments: BSH Guidelines with Dr Dima El-Sharkawi

Date of preparation: November 2022. 1122-BRU-PRC-097

An In-Depth Look at the ASPEN Study with Dr Roger Owen and Dr Shirley D’Sa

Date of preparation: November 2022. 1122-BRU-PRC-100

Practical Considerations of Brukinsa with Dr Jaimal Kothari

Date of preparation: November 2022. 1122-BRU-PRC-102

Panel Discussion with Dr Pam McKay, Dr Shirley D’Sa and Dr Dima El-Sharkawi

Date of preparation: December 2022. 1122-BRU-PRC-065

Speakers

Dr Pam McKay

Beatson West of Scotland Cancer Centre

Dr McKay is a Consultant Haematologist at the Beatson, West of Scotland Cancer Centre and an Honorary Clinical Associate Professor at the University of Glasgow School of Medicine. She has a specialist interest in lymphoma and is actively involved in lymphoma at a regional and national level. She is currently a member of the NCRI Lymphoma Clinical Studies Group and the high-grade lymphoma and Hodgkin’s lymphoma Clinical Studies Subgroups.

Dr Dima El-Sharkawi

The Royal Marsden NHS Foundation Trust

Dr Dima El-Sharkawi is a haematology consultant at the Royal Marsden Hospital. Her specialist interest is lymphoma, CLL and the mature lymphoid leukaemias. She is clinical lead for the SIHMDS at the Royal Marsden Hospital. She is the lead for the clinical advisory group for WMUK and is an author on the recently published guidelines for the diagnosis and management of Waldenstrom Macroglobulinaemia.

Dr Shirley D’Sa

UCLH Centre for Waldenström’s Macroglobulinaemia (WM)

Shirley D’Sa, MD, FRCP, FRCPath, is a Consultant Haematologist and Clinical Lead for the UCLH Centre for Waldenström’s macroglobulinemia (WM) and Related Conditions, and Honorary Associate Professor at the UCL Cancer Institute. She is also haematological lead in the Joint Neurohaematology Service at the National Hospital for Neurology and Neurosurgery, Queen Square, London with Prof Michael Lunn a specialist in peripheral nerve diseases.

Dr Roger Owen

Leeds Teaching Hospitals NHS Trust

Consultant Haematologist at St. James University Hospital Institute of Oncology in Leeds, UK. He has a special interest in indolent lymphoma including Waldenstroms macroglobulinaemia and marginal zone lymphoma.

Dr Jaimal Kothari

Oxford University Hospitals

Adverse events should be reported

United Kingdom (incl. Northern Ireland): Healthcare Professionals are asked to report any suspected adverse reactions via Yellow Card Scheme found at www.mhra.gov.uk/yellowcard.
Ireland: Healthcare Professionals are asked to report any suspected adverse reactions via HPRA.

All adverse events (UK and Ireland) should also be reported to BeiGene at [email protected]; (UK: 08009176799; Ireland: 1800812061).

For medical information, please contact: UK: 08004320266, Ireland: 1800946589 or email: [email protected]

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

September 2023 [0823-BRU-PRC-177]

Back to top

Brukinsa®▼ UK and Ireland healthcare professional website

This website contains information on BRUKINSA (zanubrutinib) and is intended for healthcare professionals in the UK and Ireland only.

To direct you to the most appropriate information, please confirm you are a UK or Ireland Healthcare Professional.

If you are not a UK or Ireland Healthcare Professional, you will be directed to the BRUKINSA Patient Information leaflet.

Are you a UK or Ireland Healthcare Professional?

0823-BRU-PRC-184 | September 2023

No, I am not